ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why Tilray (TLRY) Stock Is Down Today

TLRY Cover Image

What Happened?

Shares of cannabis company Tilray Brands (NASDAQ: TLRY) fell 1.8% in the morning session after the U.S. government passed a spending bill that included provisions to re-criminalize certain hemp-derived THC products. 

The last-minute provision effectively targeted intoxicating hemp products, such as Delta-8, that had been legalized under the 2018 Farm Bill. This development was viewed as a setback for Canadian cannabis companies like Tilray, which had considered the hemp-derived product segment a key pathway into the lucrative U.S. market. In response to the legislative change, Tilray stated that it expected “no material revenue impact” from the ban.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Tilray? Access our full analysis report here.

What Is The Market Telling Us

Tilray’s shares are extremely volatile and have had 85 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was about 2 months ago when the stock gained 41.4% on the news that U.S. President Donald Trump endorsed the use of cannabidiol (CBD) for senior healthcare in a social media post. 

Over the weekend, Trump posted on his Truth Social platform, suggesting that hemp-derived CBD could 'revolutionize senior healthcare' and serve as an alternative to prescription drugs. His comments acted as a major catalyst for the cannabis industry, sparking a broad rally that lifted shares of other major players like Canopy Growth and Aurora Cannabis. This endorsement fueled investor optimism regarding the potential for wider adoption of CBD products and a more favorable regulatory environment, adding to existing hopes for the reclassification of marijuana.

Tilray is down 23.6% since the beginning of the year, and at $1.12 per share, it is trading 46.9% below its 52-week high of $2.10 from October 2025.

Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.Go here for access to our full report.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.82
+0.13 (0.06%)
AAPL  271.09
+2.53 (0.94%)
AMD  219.27
-4.28 (-1.91%)
BAC  52.22
+0.20 (0.38%)
GOOG  298.95
+5.96 (2.03%)
META  591.48
+1.16 (0.20%)
MSFT  485.73
-1.39 (-0.29%)
NVDA  187.53
+1.01 (0.54%)
ORCL  220.75
-4.78 (-2.12%)
TSLA  415.08
+11.09 (2.75%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.